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DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 
78.4%, C2: 77.6%). Thus, the treatment with DQC had equal 
efficacy as CLM cream. A trend to less common post-treat-
ment VVC in the DQC-treated women was observed (DQC: 
2.5%, CLM: 7.7%; p = 0.06). Both treatments were well toler-
ated with no serious adverse events occurring.  Conclusion: 
Vaginal DQC has been shown to be equally effective as CLM 
cream, to be well tolerated with no systemic safety concerns, 
and is therefore a valid alternative therapy for women with 
BV [ClinicalTrials.gov, Med380104, NCT01125410]. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Bacterial vaginosis (BV) is the most common cause 
responsible for 20–40% of recurrent vaginal infections in 
women of childbearing age  [1] . BV is a synergistic poly-
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 Abstract 
 Aims: To investigate if vaginal application of dequalinium 
chloride (DQC, Fluomizin  ) is as effective as vaginal clinda-
mycin (CLM) in the treatment of bacterial vaginosis (BV). 
 Methods: This was a multinational, multicenter, single-blind, 
randomized trial in 15 centers, including 321 women. They 
were randomized to either vaginal DQC tablets or vaginal 
CLM cream. Follow-up visits were 1 week and 1 month after 
treatment. Clinical cure based on Amsel’s criteria was the pri-
mary outcome. Secondary outcomes were rate of treatment 
failures and recurrences, incidence of post-treatment vulvo-
vaginal candidosis (VVC), lactobacillary grade (LBG), total 
symptom score (TSC), and safety.  Results: Cure rates with 
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microbial syndrome characterized by depletion of  Lacto-
bacillus spp., especially those producing hydrogen perox-
ide, and an intense increase in the quantity of commen-
sally anaerobic bacteria, such as  Gardnerella vaginalis 
and other anaerobic Gram-negative rods  [2, 3] . BV is as-
sociated with serious sequelae including increased sus-
ceptibility for sexually transmitted infections, develop-
ment of pelvic inflammatory disease, and complications 
in pregnancy  [3, 4] . A high recurrence rate of BV impairs 
the quality of life of affected women. The precise etiology 
of this syndrome is not well understood, and whether
a shift in the existing vaginal flora or infection by oth-
er microbes leads to the development of BV is not clear 
 [3, 4] .
 Currently, there are two internationally recommend-
ed first-line therapies, oral metronidazole or vaginal 
clindamycin (CLM)  [5, 6] , with similar 1-month cure 
rates of 60–90%  [7, 8] . However, 15–30% of women have 
symptomatic recurrence 30–90 days following therapy, 
and 50–70% within 6–12 months  [7, 8] . In addition, 12–
24% of women develop vulvovaginal candidosis (VVC) 
following treatment  [9, 10] . Increasing resistance against 
current therapies has been described by several investiga-
tors  [11–14] . Goldstein et al.  [12, 13] reported an increase 
of  G. vaginalis resistance to metronidazole from 20 to 
29% between 1993 and 2003. Another important and fre-
quent microorganism in BV flora,  Atopobium vaginae , is 
less responsive to metronidazole than to CLM  [15] .
 Dequalinium chloride (DQC), a quaternary ammoni-
um compound, has a wide range of antimicrobial activity 
against Gram-positive and -negative bacteria, fungi and 
protozoa  [16, 17] . Its primary mode of action is the dis-
ruption of cell permeability and the subsequent loss of 
enzymatic activity  [18] . The antimicrobial activity of 
DQC has been assessed in vitro, and the minimum inhi-
bition concentrations against relevant vaginal pathogens 
have been established  [16, 17] . The clinical efficacy and 
safety of DQC in the form of a vaginal tablet (Fluomi-
zin  ) or vaginal ovula in the treatment of BV and VVC 
have been previously demonstrated  [19, 20] .
 The objective of this study was to compare the clinical 
efficacy and safety of vaginal tablets containing 10 mg 
DQC (Fluomizin) and CLM vaginal cream (2%) in wom-
en with BV.
 Subjects and Methods 
 This was a single-blinded, randomized, active-controlled 
study with two parallel groups (DQC vs. CLM) of women with 
BV. Theoretically, women were possibly aware of which study 
drug they were using despite the blinded boxes, as one drug’s
formulation was a cream, while the other was a tablet. To over-
come possible bias in the efficacy assessment by the investigator, 
two physicians were involved during the visits: the ‘treating’ 
physician dispensed the study medication according to random-
ization code and assessed compliance and side effects, and the 
‘evaluat ing’ physician assessed the efficacy while blinded to
the type of study medication given. This clinical trial was 
register ed at EudraCT (2006-004398-89) and at ClinicalTrial.
gov (Med380104, NCT01125410). The study was conducted in 15 
centers in five countries in accordance with the Declaration of 
Helsinki and the GCP guidelines, and approved by all local Eth-
ics Committees. All women gave written informed consent and 
were enrolled into the study from January 2007 to July 2008. 
This report complies with the CONSORT guidelines.
 Premenopausal women aged 18–55 years were eligible for the 
study; 1 women aged 16 was included with the consent of her
parents. To be included in the study, women had to be diagnosed 
with BV, for which all 4 Amsel criteria  [21] had to be present: (1) 
characteristic grey, homogeneous, malodorous discharge, (2) pH
 1 4.5, (3) a positive KOH test for amines, and (4) clue cells (posi-
tive if  6 20% of the epithelial cells of the wet mount were clue 
cells). Women were required to use effective contraception, but 
not involving materials sensitive to mineral oil. Exclusion criteria 
were pregnancy, lactation, hypersensitivity to the medications, 
uterine or vaginal bleeding, acute genital tract infections, ulcer-
ations, VVC, use of anti-infectious or any vaginal medication, 
vaginal douches, genital malignancies, suspicion of or clinically 
manifested sexually transmitted infections, enteritis, ulcerative 
colitis or medical history of antibiotics-induced colitis. The study 
included one screening and two follow-up visits. Women were 
randomized to receive 10 mg DQC vaginal tablets (Fluomizin) for 
6 days or CLM vaginal cream (2%) for 7 days. Follow-up visits 
took place 7 days (C1) and 25 days (C2) after the end of treatment. 
At C1 and C2, safety and tolerability of the medication were as-
sessed by the ‘treating’ physician, whereas the ‘evaluating’ physi-
cian, blinded to the study medication, performed vaginal exami-
nation and assessed the efficacy variables. The primary efficacy 
outcome was clinical cure at C1 defined as absence of clue cells 
and a negative result for at least 2 other Amsel criteria. Secondary 
efficacy outcomes were clinical cure at C2, clinical improvement 
at C1 and C2 (2 or more Amsel criteria being negative), all single 
Amsel criteria, rate of treatment failures at C2 (recurrences and 
non-responders), incidence of clinical VVC, cultural presence of 
 Candida , and lactobacillary grade (LBG). LBG evaluation was 
done by each investigator and LBGs were classified according to 
Donders et al.  [22] as normal, grade-I flora (LBG I), intermediate, 
grade-II flora (LBG II), and abnormal, grade-III flora (LBG III). 
Furthermore, total symptom score (TSC; calculated as the sum of 
the individual scores (0–3) for discharge, pruritus and burning) 
and global assessment of efficacy were evaluated. Treatment com-
pliance was assessed using a patient’s diary. Safety (SAF) out-
comes were incidence of adverse events (AEs), serious AEs, and 
adverse drug reactions (ADRs) as well as global assessment of tol-
erability.
 The study used a two-stage adaptive design according to Bau-
er and Köhne  [23] with a pre-specified interim analysis to adapt 
the sample size. The initial sample size was based on the primary 
variable and a power of 90%. The primary analysis was the per-
protocol-set (PPS) analysis performed for clinical cure rate at C1. 
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Clinical cure rates were analyzed both for the PPS and the inten-
tion-to-treat (ITT) population. All other efficacy variables were 
analyzed based on ITT population. Safety analysis included all 
women who received at least one dose of the study medication. 
Clinical cure and clinical improvement rates were tested for non-
inferiority (15% inferiority margin; one-sided test, 2.5% signifi-
cance level) applying the maximum likelihood test according to 
Farrington and Manning  [24] . Due to the two-stage adaptive de-
sign, a critical value c    of 0.0038 for the product of the maximum 
likelihood p values from the first (interim analysis) and second 
(data after interim analysis) step was used, and the two-sided 95% 
confidence intervals (with a pre-specified non-inferiority margin 
of –15%) for the complete study population (overall cure rate) was 
determined. Non-inferiority was demonstrated if p 1  ! p 2  ^  c    = 
0.0038 and the two-sided 95% confidence interval (CI 95%diff ) was 
[–15%; 15%]. TSC and global efficacy were compared by the 
Mann-Whitney test  [25] . For other secondary efficacy variables, 
the   2 test was performed. Other demographic and safety param-
eters were analyzed descriptively.
 Results 
 Demographics and baseline characteristics of the two 
study groups were comparable ( table 1 ). A total of 321 
women were randomized to receive either DQC (n = 164) 
or CLM (n = 157) ( fig. 1 ). The mean time between end of 
treatment and control visits were 7 days (C1) and 25 days 
(C2), respectively. The SAF population included 316 
women, 163 in the DQC group and 153 in the CLM 
group. One woman randomized to the CLM group was 
excluded from the ITT population since she withdrew 
her consent after 1 day of treatment. After a blind data 
review, 64 women from the ITT population were identi-
fied having major protocol deviations, leading to an ex-
clusion from the PPS population (n = 28 in the DQC 
Table 1.  Patient demographics (ITT, n = 315)
DQC 
(n = 163)
CLM 
(n = 152)
Median age, years (range) 32 (16–54) 31 (18–60)
Caucasian, n (%) 163 (100) 150 (98.7)
Mean weight, kg (SD) 62.8 (10.2) 62.4 (11.3)
Mean BMI (SD) 22.3 (3.3) 22.4 (3.7)
Women with prior vaginal infection
≥1 prior BV, n (%) 113 (69.3) 109 (71.7)
0 prior vaginal infection, n (%) 39 (23.9) 36 (23.7)
Hormonal contraception, n (%) 105 (64.4) 105 (69.1)
S D = Standard deviation; BMI = body mass index.
Screened
(n = 322)
Randomized
(n = 321)
DQC
(n = 164)
CLM
(n = 157)
No study medication used
(n = 1)
Other major deviations
(n = 28)
SAF
DQC
(n = 163)
SAF
CLM
(n = 153)
ITT
DQC
(n = 163)
ITT
CLM
(n = 152)
PPS
DQC
(n = 135)
PPS
CLM
(n = 116)
Screening failure
(n = 1)
Other major deviations
(n = 36)
Patient withdrawal, 1 day of
treatment (n = 1)
No study medication used
(n = 2)
Withdrawal of consent
(n = 1)
Patient withdrawal
(n = 1)
 Fig. 1. Patient disposition.  
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group, n = 36 in the CLM group; one or more violations 
per woman were possible). The most common protocol 
deviations were time window violations (n = 12 in both 
groups), prior termination (DQC: n = 5; CLM: n = 9), the 
investigator acted as ‘treating’ and ‘evaluating’ physician 
for the same woman (DQC: n = 9; CLM: n = 7) and vio-
lations of inclusion or exclusion criteria (DQC: n = 4; 
CLM: n = 6). There were no apparent differences in ma-
jor protocol violations between the groups. Therefore, 
the PPS population included 135 women in the DQC 
group and 116 women in the CLM group. From the ITT 
population, 13 women in the DQC group and 15 in the 
CLM group did not complete the study. Based on the pa-
tient’s diary, 95.1% of women in the DQC group and 
88.9% in the CLM group complied with the treatment 
schedule.
 Clinical cure rates at C1 (primary variable) in the PPS 
population were 81.5% in women treated with DQC and 
78.4% in CLM-treated women ( table 2 ). The CI 95%diff for 
the difference in clinical cure of DQC and CLM was 
[–6.9%; 13.0%], and thus within the pre-specified non-
inferiority margin of  8 15%. Therefore, non-inferiority of 
DQC versus CLM was demonstrated.
 At C2, the clinical cure rates observed in the PPS pop-
ulation were 79.5% with DQC and 77.6% with CLM, 
CI 95%diff = [–8.3%; 12.2%], demonstrating efficacy of 
DQC was not inferior to that of CLM. For the ITT popu-
lation, overall cure rates at C1 and C2 were comparable 
supporting the PPS results ( table  2 ). Clinical improve-
ment rates in DQC- and CLM-treated women were 88.6 
and 92.3% at C1 (CI 95%diff = [–10.8%; 3.5%]), and 79.3 and 
85.3% at C2 (CI 95%diff = [–14.8%; 2.9%]). Other secondary 
efficacy variables are shown in  table 3 . Most Amsel crite-
ria were comparable without relevant differences be-
tween the groups. Only at C1, vaginal pH was significant-
ly more often below 4.5 in the DQC group than in the 
CLM group (p = 0.02). The rate of non-responders at C2 
in the DQC group was slightly lower than in the CLM-
treated women, whereas the rate of recurrences was 
slightly higher with DQC than with CLM, but none of 
these differences were significant. The total failure rate 
(non-responders and recurrences combined) was similar 
for DQC and for CLM.
 During the complete study, 4 women (2.5%) in the 
DQC group and 11 (7.7%) in the CLM group were diag-
nosed with symptomatic, culture positive VVC (p = 0.06). 
The numbers of women in each group showing symp-
toms of clinical VVC or positive cultures for  Candida spp. 
were not significantly different ( table 3 ). However, both 
numbers increased from C1 to C2 in the CLM group, but 
not in the DQC group.
 At entry, about 75% of women in both groups present-
ed with an abnormal LBG III flora. This percentage of 
women was strongly reduced after the treatment in both 
groups ( table 3 ). The cure rates at C2 for women with LBG 
III at entry were similar to the entire population, i.e. 
74.2% in the DQC group and 70.9% in the CLM group. 
No significant difference between the groups was ob-
Table 2. C linical cure rate
Total, n Missing, n Cured, n Cure rate, % CI95%diff Difference DQC – CLM, p1 ! p2
Follow-up visit C1
PPS
DQC 135 – 110 81.5 p1 (0.02202) ! p2 (0.00177) = 0.00004CLM 116 – 91 78.4 –0.07, 0.13
ITT
DQC 163 5 126 79.7 p1 (0.02127d) ! p2 (0.00172) = 0.00004CLM 152 11 111 78.7 –0.08, 0.10
Follow-up visit C2
PPS
DQC 135 3 105 79.5 p1 (0.00718c) ! p2 (0.02317) = 0.00017CLM 116 – 90 77.6 –0.08, 0.12
ITT
DQC 163 8 116 74.8 p1 (0.00398d) ! p2 (0.08305) = 0.00033CLM 152 9 107 74.8 –0.10, 0.10
p1 ! p2 = Product p values from the first (interim analysis) and second (data after interim analysis) step: non-inferiority if <0.0038.
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served regarding LBG. Mean TSC decreased in both 
groups from approximately 4 at entry visit to  ^  1 at C2 in 
both treatment groups (p = 0.08;  table 3 ). There were no 
differences in the global efficacy assessments by investi-
gator and patient ( table 4 ).
 During this study, no serious AEs were observed. 
Fewer AEs were experienced by women treated with 
DQC (134) than by women treated with CLM (163) and 
a lower proportion of women in the DQC group report-
ed at least one AE, but none of these differences in AEs 
and ADRs were statistically significant ( table  5 ). The 
most frequently reported ADRs in both the DQC- and 
CLM-treated women were vaginal discharge (9.2 and 
4.6% of women, respectively) followed by vulvovaginal 
pruritus (4.9 and 8.5% of women, respectively). At visits 
C1 and C2, the majority of investigators and women 
( 1 90%) judged the overall tolerability of treatment as 
very good or good, with no apparent difference between 
the groups.
 Discussion 
 In this study, we have shown that treatment of BV 
with a 6-day course of vaginal tablets containing 10 mg 
DQC (Fluomizin) has equal efficacy as a 7-day course of 
CLM vaginal cream (2%). Clinical cure rates at 1 week 
after the end of therapy (C1) were similar in both groups. 
Also the cure rates at about 4 weeks after the end of 
therapy (C2) were comparable in both treatment groups. 
We used a very stringent definition for BV diagnosis in 
order to be included in the study: all 4 Amsel criteria had 
to be positive. Therefore, women with partial BV  [26] or 
in whom diagnosis was not 100% sure were not includ-
ed. Similarly, the criteria for establishing clinical cure 
required absence of clue cells and a negative result for at 
least 2 other Amsel criteria, adding to the strength of 
this study.
 The efficacy of CLM has been assessed in previous 
clinical studies mainly by using only 3 of the 4 Amsel cri-
teria (pH  1 4.5, clue cells, and KOH test). In ten clinical 
studies with CLM a total of 600 women have been treated; 
the clinical cure rate (absence of the 3 criteria) was 53.4% 
(37–72%) and the clinical improvement rate (not more 
Table 3. S econdary efficacy variables (ITT, n = 315)
DQC 
(n = 163)
CLM 
(n = 152)
p 
value*
Amsel criteria, n (%)
Discharge
C1 29 (18.4) 19 (13.3) 0.23
C2 30 (20.0) 23 (16.8) 0.48
Vaginal pH >4.5
C1 65 (41.1) 78 (54.5) 0.02
C2 57 (38.0) 60 (43.8) 0.32
Clue cells >20%
C1 21 (13.3) 16 (11.2) 0.58
C2 25 (16.7) 19 (13.9) 0.51
Positive KOH test
C1 17 (10.8) 15 (10.5) 0.94
C2 25 (16.7) 17 (12.4) 0.31
Non-responders and recurrences, n (%)
Non-responders 17 (10.4) 23 (15.2) 0.21
BV recurrence 22 (13.5) 14 (9.2) 0.23
Total failures 39 (23.9) 37 (24.3) 0.93
Incidence of clinical VVC, n (%)
C1 5 (3.2) 4 (2.8) 1.00
C2 4 (2.7) 8 (5.8) 0.24
Presence of Candida spp., n (%)
Entry 12 (7.4) 8 (5.3) 0.45
C1 21 (13.3) 16 (11.2) 0.58
C2 14 (9.3) 20 (14.6) 0.17
LBG, n (%)
Entry
LBG I 1 (0.6) 1 (0.7)
LBG II 37 (22.7) 38 (25.0)
LBG III 125 (76.7) 113 (74.3) 0.89
C1
LBG I 90 (57.0) 79 (55.2)
LBG II 49 (31.0) 38 (26.6)
LBG III 19 (12.0) 24 (16.8) 0.42
C2
LBG I 101 (67.3) 80 (58.4)
LBG II 33 (22.0) 40 (29.2)
LBG III 16 (10.7) 16 (11.7) 0.30
TSC, mean 8 SD (n)
Entry 3.782.0 (163) 4.182.0 (152) 0.14
C1 1.081.7 (158) 1.081.7 (142) 0.58
C2 0.781.4 (150) 1.081.7 (137) 0.08
* 2 test or Fisher’s exact test.
Table 4. G lobal efficacy (ITT, n = 315)
DQC (n = 163) CLM (n = 152) p value*
Investigators, very good or good
C1, n (%) 117 (74.1) 106 (74.1) 0.84
C2, n (%) 104 (69.3) 98 (71.5) 0.27
Patients, very good or good
C1, n (%) 131 (82.9) 110 (76.9) 0.41
C2, n (%) 111 (74.0) 103 (75.2) 0.59
* 2 test.
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than 1 positive) was 73.4% (65–94%)  [8] . Using this defi-
nition for the cure rate at C2, 60.0% of women treated 
with DQC and 53.3% in the CLM group were cured in the 
current study. To facilitate the comparison of our results 
with previous study results for CLM and metronidazole, 
differently defined cure and improvement rates are sum-
marized in  table 6 . Overall, based on the various defini-
tions, the cure rates observed in our study were compa-
rable with the ones of previous reports using CLM and/
or metronidazole  [3, 8, 27] .
 Recurrence of BV is known to occur commonly, re-
gardless of which antibiotic treatment is used  [3, 27] . 
Analysis of non-responders and BV recurrence at visit C2 
showed no significant difference between DQC- and 
CLM-treated women. We also assessed secondary efficacy 
parameters including clinical improvement, TSC, indi-
vidual Amsel criteria and LBG. DQC showed consistently 
equal efficacy as vaginal CLM for the treatment of BV, ex-
cept for the vaginal pH. There were significantly more 
women with a normal vaginal pH at C1 in the DQC group 
than in the CLM group. This finding together with a trend 
for a higher percentage of women with LBG I at C2 might 
indicate a better recovery of the normal vaginal flora un-
der DQC therapy. It is known that CLM may have a det-
rimental effect on lactobacillary species, making it more 
timely (up to 1 month) and difficult to obtain a full recov-
ery of the normal flora  [28] . This has led some authors to 
advocate the use of probiotics after CLM treatment to has-
ten the full recovery of the vaginal flora  [29, 30] .
 The number of women with subsequent VVC was low 
in both groups as compared to previous reports  [9, 10] . 
There was no statistical difference between the groups 
regarding symptoms of clinical VVC or positive cultures 
for  Candida spp. However, the difference between the 
groups regarding women diagnosed with clinical VVC 
and concomitant positive culture was at the limit of the 
statistical significance.
Table 5. F requently reported adverse events (n = 316)
DQC 
(n = 163), n (%)
CLM 
(n = 153), n (%)
p value*
Adverse events (AEs)
Number of AEs 134 163
Number of women with AEs 66 (40.5) 73 (47.7) 0.20
Related AEs
Number of related AEs 54 48
Number of women with related AEs 29 (17.8) 31 (20.3) 0.58
* Fisher’s exact test.
Table 6. C ure rate comparison (ITT, n = 315)
Follow-up visit C1 F ollow-up visit C2
DQC (n = 163) CLM (n = 152) p value* DQC (n = 163 ) CLM (n = 152) p value*
Based on all 4 Amsel criteria
Cureda – no clue cells and ≥2 others negative 79.7% 78.7% 0.83 74.8% 74.8% 1.00
Cured – all 4 negative 52.9% 41.8% 0.06 56.7% 50.4% 0.29
Improved – ≥3 of 4 negative 80.4% 79.4% 0.84 79.3% 80.0% 0.89
Based on 3 Amsel criteriab
Cured – all 3 negative 58.2% 44.0% 0.01 60.0% 53.3% 0.26
Improved – ≥2 of 3 negative 84.2% 83.7% 0.91 80.7% 83.8% 0.49
*  2 test. a Primary efficacy variable of this study. b pH >4.5, clue cells, KOH test.
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 The safety profiles of the two study treatments were 
similar in terms of the types of AEs, and no significant 
difference was observed regarding the incidence of AEs 
and ADRs.
 Metronidazole and CLM taken orally or applied vagi-
nally are the current mainstays of therapy for BV. How-
ever, both are ineffective in approximately 10–40% of pa-
tients,  [3, 27] are associated with a high recurrence rate  [7, 
8] , an increased likelihood of post-treatment VVC  [9, 10] , 
and not devoid of a risk of developing resistance, espe-
cially if given repetitively  [11–14] . DQC is an anti-infec-
tive agent with a different mode of action, targeting the 
microbial cytoplasm membrane and leading to release of 
cellular components  [18] . Due to this general mode of ac-
tion, DQC comprises a broader spectrum of antimicro-
bial activity than most antibiotics and exerts a rapid mi-
crobiocidal action against a variety of pathogens  [16, 17] . 
We have shown in our study that DQC is as effective as 
one of the recommended regimens with maybe a faster 
recovery of the normal vaginal flora. 
 Fluomizin vaginal tablets containing 10 mg DQC may 
have the following advantages: it has a broad antimicro-
bial spectrum, it is less vulnerable to resistance, a high 
concentration of the substance at the infection site can be 
achieved, while systemic exposure is negligible. All this 
can offer a strong benefit for the treatment of women with 
BV, particularly also as a safe therapeutic alternative dur-
ing pregnancy.
 We conclude that treatment with vaginal tablets con-
taining 10 mg DQC (Fluomizin) results in similar cure 
rates as one of the current standard therapies for BV and 
is well tolerated with no systemic safety concerns. There-
fore, DQC is a valid treatment for BV as it is CLM vaginal 
cream (2%).
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